The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

which also sells a version of liraglutide approved for obesity, called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Saxenda is a brand-name injectable solution prescribed for long-term weight management in adults and some children. It contains the active ingredient liraglutide. Saxenda is not safe to use during ...

Approval of the once-daily injection, as an adjunct to diet and exercise, is intended to help with drug shortages and improve ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Novo Nordisk’s Saxenda has been recommended ... overtaking Novo Nordisk’s older Victoza (liraglutide) product which requires dosing by injection every day. Ozempic is squaring off in the ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy Xultophy. While a newer class of GLP-1s based on Novo’s semaglutide ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...